Open Label Phase II Trial of Cabozantinib in Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC) and Known Amplifications or Activating Mutations in Gene Targets of Cabozantinib who have Received Prior Anti Androgen Therapy
Sponsor: |
Weill Cornell |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAT7368 |
U.S. Govt. ID: |
NCT04631744 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of prostate cancer. Cabozantinib (Cometriq, Cabometyx) is an oral medication that blocks activity of specific proteins in the body. It is approved by the Food and Drug Administration (FDA) for use in patients with medullary thyroid carcinoma and advanced renal cell carcinoma but is not approved to treat prostate cancer.
This study is closed
Investigator
Mark Stein, MD
Are you at least 18 years old? |
Yes |
No |
Have you been diagnosed with prostate cancer? |
Yes |
No |
Have you previously received Anti Androgen Therapy? |
Yes |
No |